Strategic Objectives
• Decode the complex chemical structures of marine-derived secondary metabolites.
• Understand the precise pharmacological pathways that halt cancer cell proliferation.
• Navigate the rigorous journey from deep-sea discovery to FDA-approved clinical trials.
• Identify the unique marine organisms providing the next generation of cytotoxic agents.
The Core Challenge
Traditional synthetic drug discovery is hitting a wall, leaving oncologists and patients searching for more potent, targeted, and less toxic therapeutic options.
01
The Blue Frontier
02
Secondary Metabolites Defined
03
Nature’s Architects
04
Benthic Powerhouses
05
The Bryostatin Legacy
06
Tunicate Therapeutics
07
The Dolastatin Family
08
Molecular Scaffolding
09
Mechanism of Action: Cytotoxicity
10
Triggering the End
11
Signal Transduction
12
Targeting the Tubulin
13
Antibody-Drug Conjugates
14
Marine Microbes
15
Extraction and Purification
16
The Supply Problem
17
Preclinical Evaluation
18
Navigating Clinical Trials
19
Pharmacokinetics of Sea-Derived Drugs
20
Combinatorial Chemistry
21
The Future of Marine Oncology
Explore Research Ecosystem
Available eBook Editions
Arabic
English
French
German
Italian
Japanese
Korean
Portuguese
Spanish
